Abstract
Transurethral surgery is the primary treatment for patients with superficial bladder cancer. Either electrical or laser thermal destruction is used most often but there is no proven therapeutic benefit for one method over the other. Treatment failure is usually a consequence of new tumor occurrence rather than the failure to eradicate existing visible tumors. Adjuvant intravesical chemotherapy or immunotherapy improves results over surgery alone in most circumstances.
MeSH terms
-
Administration, Intravesical
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / therapeutic use
-
Carcinoma in Situ / drug therapy
-
Carcinoma in Situ / pathology
-
Carcinoma in Situ / surgery
-
Carcinoma in Situ / therapy
-
Carcinoma, Transitional Cell / drug therapy
-
Carcinoma, Transitional Cell / pathology
-
Carcinoma, Transitional Cell / surgery
-
Carcinoma, Transitional Cell / therapy
-
Chemotherapy, Adjuvant
-
Electrocoagulation
-
Humans
-
Immunotherapy
-
Laser Coagulation
-
Laser Therapy
-
Neoplasm Recurrence, Local / pathology
-
Neoplasm Staging
-
Neoplasm, Residual
-
Treatment Failure
-
Urethra / surgery
-
Urinary Bladder Neoplasms / drug therapy
-
Urinary Bladder Neoplasms / pathology
-
Urinary Bladder Neoplasms / surgery*
-
Urinary Bladder Neoplasms / therapy